Description
Sutter and AstraZeneca have a multi-year research collaboration to understand how patients and care teams can create and manage a personalized care plan that improves medication adherence and outcomes in cancer. Patients struggle with remaining adherent to oral oncology medications. The regimens can be more complex (e.g., are not daily doses but rather schedules that involve cycles on and off of therapy) which not only increases the risk of non-adherence but also the risk of over-medication with the associated serious adverse events. In oncology care, non-adherence can lead to catastrophic and costly outcomes.
The objective of this research project is to design, implement, and evaluate the impact of a comprehensive oral oncology medication management tool. This tool, called MediConnect, is aimed at empowering patient-provider communication, improving patient adherence and safety and compliance to prescribed oral chemotherapy medications, and supporting patients and providers in navigating the complex oncology care processes.
Digital Tool: Mobile Application
MediConnect helps you manage your oral chemo medications at home. MediConnect is free to download and use as part of this Sutter Health closed research pilot study.
Through the app, you can report whether you have taken a medicine and the reason for not taking it. You will be reminded when it is time to take your next dose and see a calendar view of your medication schedule and future doses to help you plan. Information you enter in the app will be sent to a dashboard for your care team to review.
Key Features:
Report medication delivery
Report medication start date
Report medication taken
Report barriers
See your care team contact info
Receive reminders when to take your next dose
Find helpful resources if you run into trouble
You will need an active My Health Online account before you can start using the app. If you do not have a My Health Online account, you can find out how to register at: https://mho.sutterhealth.org
Principal Investigator
Rajesh Behl, M.D., J.B. Jones, PhD, MBA
Co-Investigator(s)
Recruitment Information
To use the MediConnect app, you must consent to be a part of the research study. Please check with your Sutter Health care team if you'd like to use the app.
To report if something is not working in the app, use the email below to contact the project team.
Note: Please do not use this email for medication questions. This email WILL NOT go to your care team.
By Email: MediConnect@sutterhealth.org
By Phone: (916) 297-8919
Funder
AstraZeneca Pharmaceuticals LP
Research Topics
Related Studies
Cancer Liquid Biopsy Monitoring Study
Investigators: Mohammed Kashani-Sabet, M.D., Deepti Behl, MD
COVID-19 Impacts on Cancer Care Management, Patient Experience and Care Costs
Investigators: Cheryl Stults, Ph.D., Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.
Stupski Serious Illness Program Evaluation
Investigator: Sylvia Sudat, PhD
Improving Cancer Care
Investigator: Su-Ying Liang, Ph.D.
Multilevel Study of Lung Cancer Screening Guidelines Implementation (MUST)
Investigator: Jiang Li, Ph.D., MPH
Implementing Universal Lynch Syndrome Screening Across Multiple Healthcare Systems: Identifying Strategies to Facilitate and Maintain Programs in Different Organizations Contexts
Investigators: External PI, Principal Investigator, Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.
Lung Cancer in Never Smokers: Incidence, Risk Factors and Molecular Characteristics in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Women
Investigators: External PI, Principal Investigator, Su-Ying Liang, Ph.D.
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: Xiaowei (Sherry) Yan, PhD, MS, External PI, Principal Investigator
Dana Farber 13-09-259 DCIS Registry
Investigator: Kristie A. Bobolis, M.D.